QLC1101 + QL1203

QLC1101 + QL1203 is an investigational combination therapy being evaluated for the treatment of patients with advanced solid tumors harboring a KRAS G12D mutation. **QLC1101** is a selective, reversible, oral small-molecule inhibitor targeting the KRAS G12D mutant protein, an oncogenic driver found in several cancer types. **QL1203** is a monoclonal antibody that targets the epidermal growth factor receptor (**EGFR**), functioning as an EGFR modulator. The combination leverages potential synergistic effects by simultaneously inhibiting KRAS-driven oncogenic signaling and blocking the EGFR pathway, which may improve efficacy in tumors with KRAS G12D mutations compared to single-agent therapy. The regimen is developed by Qilu Pharmaceutical and is currently being studied in a Phase Ib/II clinical trial for advanced solid tumors with KRAS G12D mutations, with a focus on safety, tolerability, and efficacy[1][3][5][7][9].

Other names

QLC1101 + QL1203